Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04626635 |
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2020-11-12 |
Location
California, United States
Colorado, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey (Türkiye) |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
cemiplimab, REGN7075 |
Tags
MSS/ MMRp
|
| NCT ID NCT01174121 |
TitleImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Phase
Phase 2
|
Date Added 2010-08-03 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05107674 |
TitleA Study of NX-1607 in Adults With Advanced Malignancies | Phase
Phase 1
|
Date Added 2021-11-04 |
Location
California, United States
Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
NX-1607 |
Tags
MSS/ MMRp
|
| NCT ID NCT02693535 |
TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase
Phase 2
|
Date Added 2016-02-26 |
Location
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04111458 |
TitleA Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | Phase
Phase 1
|
Date Added 2019-10-01 |
Location
Massachusetts, United States
North Carolina, United States Tennessee, United States Texas, United States Germany Netherlands |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 1701963, Trametinib |
Tags
MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | Phase
Phase 2
|
Date Added 2020-10-05 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03088150 |
TitleCOLLISION Trial – Colorectal Liver Metastases: Surgery vs Thermal Ablation | Phase
Phase 3
|
Date Added 2017-03-23 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Unknown status
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05213195 |
TitleNKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2022-01-28 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
NKG2D CAR-NK |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03190941 |
TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | Phase
Phase 1, Phase 2
|
Date Added 2017-06-19 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-KRAS G12V mTCR PBL, Cyclophosphamide, Fludarabine, High-dose Aldesleukin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03785249 |
TitlePhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | Phase
Phase 1, Phase 2
|
Date Added 2018-12-24 |
Location
Alabama, United States
Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
afatinib, cetuximab, MRTX849, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
